Urotensin II: Its Function in Health and Its Role in Disease
Open Access
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 19 (1) , 65-75
- https://doi.org/10.1007/s10557-005-6899-x
Abstract
Urotensin II (U-II) is the most potent vasoconstrictor known, even more potent than endothelin-1. It was first isolated from the fish spinal cord and has been recognized as a hormone in the neurosecretory system of teleost fish for over 30 years. After the identification of U-II in humans and the orphan human G-protein-coupled receptor 14 as the urotensin II receptor, UT, many studies have shown that U-II may play an important role in cardiovascular regulation. Human urotensin II (hU-II) is an 11 amino acid cyclic peptide, generated by proteolytic cleavage from a precursor prohormone. It is expressed in the central nervous system as well as other tissues, such as kidney, spleen, small intestine, thymus, prostate, pituitary, and adrenal gland and circulates in human plasma. The plasma U-II level is elevated in renal failure, congestive heart failure, diabetes mellitus, systemic hypertension and portal hypertension caused by liver cirrhosis. The effect of U-II on the vascular system is variable, depending on species, vascular bed and calibre of the vessel. The net effect on vascular tone is a balance between endothelium-independent vasoconstriction and endothelium-dependent vasodilatation. U-II is also a neuropeptide and may play a role in tumour development. The development of UT receptor antagonists may provide a useful research tool as well as a novel treatment for cardiorenal diseases. © 2005 Springer Science + Business Media, Inc.postprinKeywords
This publication has 101 references indexed in Scilit:
- Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathyPeptides, 2004
- Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteriesPeptides, 2004
- Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteriesThorax, 2004
- Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart FailureCirculation, 2004
- Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathyInternational Journal of Cardiology, 2004
- Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar ratsCanadian Journal of Physiology and Pharmacology, 2004
- Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic ActionsHypertension, 2003
- Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonistBritish Journal of Pharmacology, 2002
- Urotensin II evokes potent vasoconstriction in humans in vivoBritish Journal of Pharmacology, 2002
- Identification of Urotensin II as the Endogenous Ligand for the Orphan G-Protein-Coupled Receptor GPR14Biochemical and Biophysical Research Communications, 1999